Jean-Pierre Routy, MD
Primary Axis:
Infection and Immunity
Email:
Email contact form Research Focus:
Dr Routy strives to bring basic laboratory research into fruitful clinical trials. The main focus is on understanding HIV pathogenesis and restoring the immune system of individuals infected with HIV. Current studies include the use of interleukin-7 (a cytokine), or a dendritic cell-based therapeutic vaccine, or chloroquine (a commonly used anti-malarial drug) in addition to antiretrovirals to optimaly manage HIV infection. He is also the principle investigator of a national cohort of patients recently infected with HIV, which aims to understand the natural history of HIV infection, concentrating on its effect in the gut.
Keywords:
HIV, Immunotherapy, therapeutic vaccine, immunology, infectious diseases, T-cell recovery, primary HIV Infection
Location:
Royal Victoria Hospital Publications:
Routy JP, Boulassel MR, Yassine-Diab B, Finke L, Nicolette L, Healey D, Jain R, Landry C, Yegorov O, Tcherepanova I, Monesmith T, Sékaly RP. Immunologic activity and safety of autologous HIV RNA–loaded dendritic cells in HIV-1 infected patients receiving antiretroviral therapy. Clin Immunol; 134:140-147, 2009.
Interleukin-2 therapy in Patients with HIV infection. The INSIGHT-ESPRIT Study Group and SILCAAT Scientific. Abrams D, Lévy Y, Losso M.H., Babiker A, Collins, G; Cooper D, Darbyshire J, Emery S, Fox L, Gordin F, Lane HC, Lundgren JD, Mitsuyasu R, Neaton JD, Phillips A, Routy JP, Tambussi G, Wentworth D. New Engl J Med; 361:1548-1559, 2009.
Said EA, Trautmann L, Dupuy FP, Zhang Y, Shi Y, Hill BJ, El-Far M, Ancuta P, Van Grevenynghe J, Boulassel MR, Routy JP, Douek DC, Haddad EK, Sekaly RP. PD-1 induced IL-10 production by monocytes impairs CD4 T-cell activation during HIV infection. Nat Med; 16: 452-459, 2010
